DNA/RNA

Description
The gene covers 220.87 kb (from 87734485 to 87955350-NCBI) and contains 48 exons and 51 different introns (49 gt-ag, 2 gc-ag), initiates transcription within exon 2 and terminates in exon 48.
Transcription
Transcription produces 13 different mRNAs, 9 alternatively spliced variants and 4 unspliced forms. RefSeq annotates 4 representative transcripts, but Homo sapiens cDNA sequences in GenBank support at least 9 spliced variants.
Protein
Description
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP is a large protein that possesses a PTP domain at C-terminus, and multiple noncatalytic domains, which include a domain with similarity to band 4.1 superfamily of cytoskeletalassociated proteins, a region consisting of five PDZ domains, and a leucine zipper motif. This PTP was found to interact with, and dephosphorylate Fas receptor, as well as IkappaBalpha through the PDZ domains, which suggested its role in Fas mediated programmed cell death. This PTP was also shown to interact with GTPase-activating protein, and thus may function as a regulator of Rho signaling pathway. Eight spliced and the unspliced mRNAs putatively encode good proteins.
Expression
In all human normal tissues, including lymph node and peripheral blood mononuclear cells samples, PTPN13 is ubiquitously expressed. 
Localisation
The FERM domain binds to phosphatidylinositol 4,5-biphosphate leading to the enrichment of PTPN13 at a juxtamembrane localization.However, the PTPN13 protein is also detected throughout the cytoplasm. In HeLa cells, PTPN13 localizes to the centrosomes during metaphase.
Function
Functionally, the gene has been tested for association to diseases (bone neoplasms; carcinoma; colorectal neoplasms; liver neoplasms; lymphoma; sarcoma, Ewing's), proposed to participate in a pathway (FAS signaling pathway (CD95)) and a process (protein amino acid dephosphorylation). Proteins are expected to have molecular functions (non-membrane spanning protein tyrosine phosphatase activity, hydrolase activity, protein binding, structural molecule activity) and to localize in various compartments (nucleus, cytoplasm, cytoskeleton).
Mutations
Note Different somatic mutations was identified in colorectal tumors (19% of the colorectal cancer samples analyzed), predicted to result in missense or non-sense mutations. Some of these mutant proteins led to reduce phosphatase activity.
Implicated in
Colorectal cancers
Disease A large-scale study that looked at the mutations in the tyrosine phosphatome from colorectal cancers identified PTPN13. The authors identified 19 mutations, non-sense and missense, seven of which were in the PTP domain.
Lymphomas (Hodgkin and nonHodgkin), gastric and hepatocellular tumors
Disease Hypermethylation of the PTPN13 promoter or allelic loss was observed leading to downregulation of PTPN13 mRNA.
To be noted
Note
Several evidences suggest that PTPN13 may act
Distribution of mutations in PTPN13, black arrows indicate location of missense mutations, red arrows indicate location of nonsense mutations or frameshifts.
PTPN13 (Protein tyrosine phosphatase, non-receptor type 13)
Beghini A Atlas Genet Cytogenet Oncol Haematol. 2009; 13(8) differently as a tumor promoting gene depending upon the disease context. The modulation of Fas-mediated cell death by PTPN13 could enhance tumor growth by blocking death signaling.
